Drugs / Biphentin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT01985581 Background | Oct 2013 → Mar 2015 | attention deficit-hyperactivity disorder | JPM van Stralen Medicine Professional | Completed | Met primary |
| — | NCT02142140 Comparator | Dec 2012 → Feb 2019 | attention deficit-hyperactivity disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT02210728 Comparator | Apr 2006 → Oct 2018 | attention deficit-hyperactivity disorder | Lily Hechtman | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biphentin | “patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗ |